TCR2 Therapeutics Inc. (TCRR)

NASDAQ: TCRR · IEX Real-Time Price · USD
2.34
-0.06 (-2.50%)
May 18, 2022 11:42 AM EDT - Market open
Market Cap90.20M
Revenue (ttm)n/a
Net Income (ttm)-107.42M
Shares Out38.55M
EPS (ttm)-2.63
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume57,233
Open2.36
Previous Close2.40
Day's Range2.31 - 2.39
52-Week Range2.10 - 20.07
Beta2.25
AnalystsBuy
Price Target16.32 (+597.4%)
Earnings DateMay 12, 2022

About TCRR

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T ce...

IndustryBiotechnology
IPO DateFeb 14, 2019
CEOGarry Menzel
Employees137
Stock ExchangeNASDAQ
Ticker SymbolTCRR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for TCRR stock is "Buy." The 12-month stock price forecast is 16.32, which is an increase of 597.44% from the latest price.

Price Target
$16.32
(597.44% upside)
Analyst Consensus: Buy
Stock Forecasts

News

TCR² Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

- Initiated Phase 2 expansion portion of the ongoing gavo-cel clinical trial- IND Clearance for Phase 1/2 clinical trial of TC-510- 30 patients treated with gavo-cel in the expanded Phase 1 trial; datas...

6 days ago - GlobeNewsWire

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from soli...

2 weeks ago - GlobeNewsWire

TCR² Therapeutics Reports Fourth Quarter 2021 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering ...

1 month ago - GlobeNewsWire

TCR² Therapeutics to Highlight Off-the-Shelf TRuC-T Cell at the American Association of Cancer Research Annual Meetin...

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from so...

2 months ago - GlobeNewsWire

TCR² Therapeutics to Present at the SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering f...

3 months ago - GlobeNewsWire

Here's Why TCR2 Therapeutics Inc. (TCRR) is Poised for a Turnaround After Losing 20.2% in 4 Weeks

TCR2 Therapeutics Inc. (TCRR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earning...

4 months ago - Zacks Investment Research

TCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy Officer

CAMBRIDGE, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from sol...

4 months ago - GlobeNewsWire

TCR² Therapeutics Announces 2022 Strategic Priorities and Anticipated Milestones

- Safety Review Team (SRT) identified gavo-cel recommended Phase 2 dose (RP2D) at 1x108 cells/m2 - Initiation of gavo-cel Phase 2 study expected in 1H 2022 with initial data in 2H 2022- Initial data fro...

4 months ago - GlobeNewsWire

TCR² Therapeutics to Present at the J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- https://investors.tcr2.com/

4 months ago - GlobeNewsWire

TCR² Therapeutics to Present at the H.C. Wainwright BioConnect Conference

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering ...

4 months ago - GlobeNewsWire

TCR² Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering f...

6 months ago - GlobeNewsWire

TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in ...

CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from sol...

6 months ago - GlobeNewsWire

TCR² Therapeutics Reviews Pipeline and Strategy at R&D Day

- gavo-cel recommended Phase 2 dose (RP2D) identification before year-end

6 months ago - GlobeNewsWire

TCR² Therapeutics to Host R&D Day on October 20, 2021

CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from can...

7 months ago - GlobeNewsWire

TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractor...

- Clinical activity observed in all three mesothelin-expressing tumor types treated

8 months ago - GlobeNewsWire

TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Soli...

CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from ca...

8 months ago - GlobeNewsWire

TCR² Therapeutics to Present at the H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from ca...

8 months ago - GlobeNewsWire

TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from ca...

8 months ago - GlobeNewsWire

TCR² Therapeutics Announces Renowned Translational Medicine Leader Priti Hegde Joins Its Board of Directors

CAMBRIDGE, Mass., Aug. 26, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from can...

8 months ago - GlobeNewsWire

Implied Volatility Surging for TCR2 Therapeutics (TCRR) Stock Options

Investors need to pay close attention to TCR2 Therapeutics (TCRR) stock based on the movements in the options market lately.

9 months ago - Zacks Investment Research

TCR² Therapeutics Announces Upcoming Medical Meetings Update

CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from can...

9 months ago - GlobeNewsWire

TCR² Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from can...

9 months ago - GlobeNewsWire

TCR² Therapeutics Appoints Cell & Gene Therapy Manufacturing Veteran Peter Olagunju as Chief Technical Officer

CAMBRIDGE, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients with solid ...

9 months ago - GlobeNewsWire

TCR² Therapeutics to Participate in Two Upcoming Conferences in June

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from canc...

11 months ago - GlobeNewsWire

TCR² Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from canc...

1 year ago - GlobeNewsWire